Arihant Senthil

Arihant Senthil

Auto-generated profile, based on publicly available information

Arihant Senthil

University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi, India

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2026 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Closed access
PDF file
KSKasana Smith
Kasana Smith
NCNaomi Châtelain
Naomi Châtelain
VPVansh Patel
Vansh Patel
HBHimanshi Banker
Himanshi Banker
GGGunn Goel
Gunn Goel
RJRohit Jain
Rohit Jain

29 July 2026 in Turkish Journal of Internal Medicine
Verified
Journal Article
Open access
ASArihant Senthil
Arihant Senthil
TPTashvin Paul
Tashvin Paul
KSKaranbir Singh
Karanbir Singh
MKMahima Kamble
Mahima Kamble
JHJinpyo Hong
Jinpyo Hong
RJRohit Jain
Rohit Jain
Objective: Hemophilia, a genetic bleeding disorder caused by deficiencies in clotting factors VIII, IX, or XI, has transitioned from a fatal disease to a chronic but manageable condition. Traditional management with plasma-derived and recombinant factor replacement improved survival and reduced bleeding but remains limited by frequent infusions, inhibitor development, and incomplete protection against joint damage.Methods: This narrative review was based on a literature search of PubMed/MEDLINE and Google Scholar, focusing on recent clinical studies, guidelines, and landmark publications on hemophilia therapies.Results: Recent therapeutic advances have transformed hemophilia management by reducing treatment burden, improving bleed prevention, and enhancing patient quality of life. Extended half-life factor concentrates have decreased infusion frequency, while non-factor therapies have expanded effective prophylaxis for patients with and without inhibitors through convenient subcutaneous administration. Gene therapy has demonstrated sustained endogenous factor expression with substantial reductions in bleeding episodes, offering the potential for long-term disease modification. Despite these advances, challenges related to treatment durability, immune responses, patient eligibility, accessibility, and cost continue to limit widespread implementation.Conclusion: This narrative review outlines the evolution of hemophilia therapy from replacement strategies to innovative mechanism-based approaches, emphasizing clinical outcomes, emerging challenges, and the imperative to translate advances into equitable, sustainable care.

11 July 2026 in Postgraduate Medicine
Verified
Journal Article
Closed access
ASArihant Senthil
Arihant Senthil
AGAarushi Gupta
Aarushi Gupta
VBVasu Bansal
Vasu Bansal
CACaroline Antony
Caroline Antony
YTYash Vardhan Trivedi
Yash Vardhan Trivedi
RJRohit Jain
Rohit Jain
Chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) are BCR:ABL1-driven hematologic malignancies that account for a substantial proportion of ...